4614 related articles for article (PubMed ID: 12377188)
1. Development of a melanoma-specific adenovirus.
McCart JA; Wang ZH; Xu H; Hu Y; Park B; Alexander HR; Bartlett DL
Mol Ther; 2002 Oct; 6(4):471-80. PubMed ID: 12377188
[TBL] [Abstract][Full Text] [Related]
2. Conditionally replication-competent adenoviral vectors with enhanced infectivity for use in gene therapy of melanoma.
Liu Y; Ye T; Sun D; Maynard J; Deisseroth A
Hum Gene Ther; 2004 Jul; 15(7):637-47. PubMed ID: 15242524
[TBL] [Abstract][Full Text] [Related]
3. Augmentation of melanoma-specific gene expression using a tandem melanocyte-specific enhancer results in increased cytotoxicity of the purine nucleoside phosphorylase gene in melanoma.
Park BJ; Brown CK; Hu Y; Alexander HR; Horti J; Raje S; Figg WD; Bartlett DL
Hum Gene Ther; 1999 Apr; 10(6):889-98. PubMed ID: 10223723
[TBL] [Abstract][Full Text] [Related]
4. Novel oncolytic adenoviruses targeted to melanoma: specific viral replication and cytolysis by expression of E1A mutants from the tyrosinase enhancer/promoter.
Nettelbeck DM; Rivera AA; Balagué C; Alemany R; Curiel DT
Cancer Res; 2002 Aug; 62(16):4663-70. PubMed ID: 12183423
[TBL] [Abstract][Full Text] [Related]
5. Adenoviral vectors with E1A regulated by tumor-specific promoters are selectively cytolytic for breast cancer and melanoma.
Zhang L; Akbulut H; Tang Y; Peng X; Pizzorno G; Sapi E; Manegold S; Deisseroth A
Mol Ther; 2002 Sep; 6(3):386-93. PubMed ID: 12231175
[TBL] [Abstract][Full Text] [Related]
6. Zinc finger and carboxyl regions of adenovirus E1A 13S CR3 are important for transactivation of the cytomegalovirus major immediate early promoter by adenovirus.
Sanchez TA; Habib I; Leland Booth J; Evetts SM; Metcalf JP
Am J Respir Cell Mol Biol; 2000 Nov; 23(5):670-7. PubMed ID: 11062146
[TBL] [Abstract][Full Text] [Related]
7. Transcriptional targeting modalities in breast cancer gene therapy using adenovirus vectors controlled by alpha-lactalbumin promoter.
Li X; Zhang J; Gao H; Vieth E; Bae KH; Zhang YP; Lee SJ; Raikwar S; Gardner TA; Hutchins GD; VanderPutten D; Kao C; Jeng MH
Mol Cancer Ther; 2005 Dec; 4(12):1850-9. PubMed ID: 16373700
[TBL] [Abstract][Full Text] [Related]
8. Anti-tumor efficacy of a transcriptional replication-competent adenovirus, Ad-OC-E1a, for osteosarcoma pulmonary metastasis.
Li X; Jung C; Liu YH; Bae KH; Zhang YP; Zhang HJ; Vanderputten D; Jeng MH; Gardner TA; Kao C
J Gene Med; 2006 Jun; 8(6):679-89. PubMed ID: 16570242
[TBL] [Abstract][Full Text] [Related]
9. Impact of E1a modifications on tumor-selective adenoviral replication and toxicity.
Sauthoff H; Pipiya T; Heitner S; Chen S; Bleck B; Reibman J; Chang W; Norman RG; Rom WN; Hay JG
Mol Ther; 2004 Oct; 10(4):749-57. PubMed ID: 15451459
[TBL] [Abstract][Full Text] [Related]
10. Combining high selectivity of replication with fiber chimerism for effective adenoviral oncolysis of CAR-negative melanoma cells.
Rivera AA; Davydova J; Schierer S; Wang M; Krasnykh V; Yamamoto M; Curiel DT; Nettelbeck DM
Gene Ther; 2004 Dec; 11(23):1694-702. PubMed ID: 15496964
[TBL] [Abstract][Full Text] [Related]
11. Adenoviral E1a expression levels affect virus-selective replication in human cancer cells.
Zheng X; Rao XM; Snodgrass C; Wang M; Dong Y; McMasters KM; Zhou HS
Cancer Biol Ther; 2005 Nov; 4(11):1255-62. PubMed ID: 16222119
[TBL] [Abstract][Full Text] [Related]
12. Analyses of melanoma-targeted oncolytic adenoviruses with tyrosinase enhancer/promoter-driven E1A, E4, or both in submerged cells and organotypic cultures.
Banerjee NS; Rivera AA; Wang M; Chow LT; Broker TR; Curiel DT; Nettelbeck DM
Mol Cancer Ther; 2004 Apr; 3(4):437-49. PubMed ID: 15078987
[TBL] [Abstract][Full Text] [Related]
13. A novel attenuated replication-competent adenovirus for melanoma therapy.
Peter I; Graf C; Dummer R; Schaffner W; Greber UF; Hemmi S
Gene Ther; 2003 Apr; 10(7):530-9. PubMed ID: 12646858
[TBL] [Abstract][Full Text] [Related]
14. Effects of the Ad5 upstream E1 region and gene products on heterologous promoters.
Hoffmann D; Jogler C; Wildner O
J Gene Med; 2005 Oct; 7(10):1356-66. PubMed ID: 15945123
[TBL] [Abstract][Full Text] [Related]
15. Gene therapy for prostate cancer by controlling adenovirus E1a and E4 gene expression with PSES enhancer.
Li X; Zhang YP; Kim HS; Bae KH; Stantz KM; Lee SJ; Jung C; Jiménez JA; Gardner TA; Jeng MH; Kao C
Cancer Res; 2005 Mar; 65(5):1941-51. PubMed ID: 15753394
[TBL] [Abstract][Full Text] [Related]
16. Construction of a novel oncolytic adenoviral vector and its biological characteristics.
Zhang M; Zhang X; Han Z; Chen X; Yang L; Sheng Y; Wen J
Oncol Rep; 2013 Feb; 29(2):798-804. PubMed ID: 23165979
[TBL] [Abstract][Full Text] [Related]
17. Efficient melanoma cell killing and reduced melanoma growth in mice by a selective replicating adenovirus armed with tumor necrosis factor-related apoptosis-inducing ligand.
Fecker LF; Rückert S; Kurbanov BM; Schmude M; Stockfleth E; Fechner H; Eberle J
Hum Gene Ther; 2011 Apr; 22(4):405-17. PubMed ID: 20977303
[TBL] [Abstract][Full Text] [Related]
18. A novel, conditionally replicative adenovirus for the treatment of breast cancer that allows controlled replication of E1a-deleted adenoviral vectors.
Hernandez-Alcoceba R; Pihalja M; Wicha MS; Clarke MF
Hum Gene Ther; 2000 Sep; 11(14):2009-24. PubMed ID: 11020800
[TBL] [Abstract][Full Text] [Related]
19. Conditionally replicative adenovirus driven by the human telomerase promoter provides broad-spectrum antitumor activity without liver toxicity.
Irving J; Wang Z; Powell S; O'Sullivan C; Mok M; Murphy B; Cardoza L; Lebkowski JS; Majumdar AS
Cancer Gene Ther; 2004 Mar; 11(3):174-85. PubMed ID: 14726958
[TBL] [Abstract][Full Text] [Related]
20. Analysis of adenovirus trans-complementation-mediated gene expression controlled by melanoma-specific TETP promoter in vitro.
Fontecedro AC; Lutschg V; Eichhoff O; Dummer R; Greber UF; Hemmi S
Virol J; 2010 Jul; 7():175. PubMed ID: 20670430
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
